
|Articles|December 1, 2003
Drug combo reduces PSA in high-risk PCa patients
Portland, OR-Weekly preoperative chemotherapy with docetaxel (Taxotere)and mitoxantrone (Novantrone) reduced PSA levels and was associated witha high rate of negative surgical margins in a small preliminary clinicaltrial involving high-risk localized prostate cancer patients.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
The UroOnc Minute: MDT for Oligometastatic Prostate Cancer, with Chad Tang, MD
2
Study suggests potential diuretic effect with nadofaragene firadenovec
3
Praful Ravi, MB, BChir, MRCP, on PSMA-PET during initial systemic therapy for mHSPC
4
Clint Bahler, MD, reflects on precision medicine and focal therapy highlights at AUA 2026
5











